How Long Does It Take Esophagitis to Heal From GERD?

Most cases of erosive esophagitis caused by GERD heal within four to eight weeks when treated with a proton pump inhibitor (PPI), with studies reporting healing rates between 75% and 95% at the eight-week mark. But that range is enormous, and where you fall in it depends on how damaged your esophagus is at the start, how your body metabolizes medication, and whether certain anatomical factors are working against you. The timeline gets more complicated the more closely you look at it.

The Standard Healing Window

When doctors talk about healing erosive esophagitis, they mean the visible damage to the esophageal lining has resolved on endoscopy, not simply that symptoms have improved. The standard course of PPI therapy, which includes drugs like omeprazole, lansoprazole, and esomeprazole, runs for eight weeks. Across the board, healing rates after this period range from about 75% to 95%, regardless of which specific PPI is used.¹ That sounds reassuring, but the wide spread reflects the fact that mild and severe cases are pooled together. Mild erosive esophagitis (classified as Los Angeles grades A and B) heals at the higher end of that range, often within four weeks. Severe cases tell a very different story.

How Severity Changes the Timeline

Esophagitis severity is graded on a scale from A to D using the Los Angeles classification system. Grade A involves small mucosal breaks under 5 millimeters, while grade D means large breaks that wrap around most of the esophageal circumference. This distinction matters enormously for healing time. A Japanese multicenter study of patients with severe esophagitis (grades C and D) found an overall healing rate of only about 68% after eight weeks of PPI treatment. Patients with grade C healed at roughly 70%, while those with grade D healed at around 58%.² Among those who didn’t fully heal, over half still showed improvement, dropping from grade C or D down to A or B. So even when healing isn’t complete, the damage often lessens.

The gap between mild and severe esophagitis widens further when comparing different PPIs. Trials comparing esomeprazole to lansoprazole found that the healing advantage of the stronger acid suppressor grew as baseline severity increased.³ In other words, for mild cases the choice of PPI barely matters, but for severe cases the specific drug and dose can meaningfully affect whether you heal in the first treatment course or need additional time. Patients with more symptomatic disease and more severe erosions were also less likely to achieve healing overall.⁴

The Acid-Suppression Threshold Your Body Needs to Hit

Healing isn’t just about taking a pill. It’s about how much of the day your stomach acid stays suppressed. A modeling study of patients with severe esophagitis found that maximal healing rates were achieved when the stomach’s pH stayed above 4 for roughly 50% to 70% of the day, which translates to about 12 to 17 hours out of every 24.⁵ Pushing acid suppression beyond that threshold didn’t improve healing further. This is useful context because it explains why some people heal on a standard PPI dose and others don’t: the question is whether the drug, at its prescribed dose, keeps your specific stomach at pH above 4 for enough of the day. If it doesn’t, you’re essentially undertreated even though you’re taking the medication as directed.

Nighttime acid exposure plays an outsized role. A study of patients with severe reflux esophagitis who failed to heal on omeprazole found they had similar daytime acid levels to those who did heal. The key difference was greater acid exposure at night while lying down.⁶ This is one reason doctors sometimes add a bedtime dose of a PPI or an H2 blocker when healing stalls.

Why Some People Don’t Heal on Standard Treatment

If you’ve taken a PPI faithfully for eight weeks and your esophagitis hasn’t resolved, you’re not alone, and the reasons often go beyond medication compliance. One important factor is genetic variation in how your liver processes PPIs. All PPIs are broken down primarily by an enzyme called CYP2C19. People who carry genetic variants that make this enzyme work faster, known as rapid metabolizers, clear the drug from their system more quickly, meaning it spends less time suppressing acid. A meta-analysis found that rapid metabolizers with reflux esophagitis had a significantly higher risk of failing PPI therapy compared to people who metabolize the drug slowly.⁷ One study showed that rapid metabolizers with erosive esophagitis had more than double the residual symptom scores of other genotypes while on maintenance PPI therapy.⁸

Despite strong evidence that CYP2C19 genotype influences treatment outcomes, current gastroenterology guidelines do not recommend genetic testing before prescribing PPIs.⁹ In practice, this means most people who are rapid metabolizers discover it indirectly, when their standard PPI dose simply doesn’t work well enough. The usual clinical response is to increase the dose or switch to a different PPI rather than order a genetic test.

Anatomy matters too. Patients with a hiatal hernia have a harder time healing because the hernia disrupts the lower esophageal sphincter and allows more acid to contact the esophageal lining. Research has shown that the degree of esophagitis is proportional to the size of the hernia, and that larger hernias lead to more prolonged acid exposure and worse acid clearance.¹⁰ A large hiatal hernia doesn’t make healing impossible, but it can mean you need a higher PPI dose or a longer treatment course to get there.

A Newer Drug Class That Heals Faster

Vonoprazan, a potassium-competitive acid blocker (P-CAB), works differently from PPIs. Rather than needing to be activated by acid, it blocks the acid pump directly and reaches full effect faster. In a randomized trial of over 1,000 patients, vonoprazan healed erosive esophagitis in about 93% of patients compared to roughly 85% for lansoprazole at eight weeks. The difference was especially striking for severe cases: at just two weeks, vonoprazan was already about 18 percentage points ahead of lansoprazole for healing grade C and D disease.¹¹

A systematic review comparing vonoprazan to various PPIs confirmed this pattern. The odds of healing at eight weeks were consistently higher with vonoprazan, and the advantage was most pronounced in patients with severe baseline esophagitis.¹² Vonoprazan is also unaffected by CYP2C19 metabolism, which means it sidesteps the genetic variability problem that undermines PPIs in rapid metabolizers. For people who haven’t healed on a standard PPI course, vonoprazan represents a genuine change in what’s possible, though it’s still relatively new and not yet available in every country.

Feeling Better Doesn’t Always Mean Healed

One of the trickier aspects of esophagitis healing is the disconnect between how you feel and what’s actually happening in your esophagus. Your heartburn might resolve within a few days of starting a PPI, which is a relief, but the mucosal damage takes considerably longer to repair. The reverse is also true: some people whose esophagitis has healed on endoscopy still report reflux symptoms. Clinical trials have shown that a substantial number of patients who become asymptomatic on treatment continue to have abnormal acid exposure and visible erosive esophagitis when checked objectively.¹³

This matters for a practical reason. If you stop your medication because you feel fine after two or three weeks, your esophagus may not have had enough time to fully heal, even though your symptoms have resolved. Completing the full course your doctor prescribed, typically eight weeks, gives the tissue the best chance of recovery.

The Relapse Problem

Healing erosive esophagitis is one thing. Keeping it healed is another. GERD is a chronic condition driven by structural and functional problems, meaning the same acid exposure that caused the damage in the first place tends to return once you stop suppressing it. Relapse rates after stopping PPI therapy are high: roughly 50% to 80% for patients with mild erosive esophagitis or non-erosive reflux disease. For patients with grade C esophagitis, the relapse rate approaches 100% within six months.¹⁴ This is why many people with moderate or severe erosive esophagitis end up on long-term maintenance therapy rather than a single treatment course.

For people with mild disease, “on-demand” therapy, where you take a PPI only when symptoms return, can work about as well as daily treatment. A systematic review found that on-demand and continuous therapy had similar failure rates in patients with non-erosive reflux disease and mild erosive esophagitis, and on-demand users took about half as much medication.¹⁵ But the same review found that continuous daily therapy was clearly better for severe esophagitis, with the benefit of continuous treatment increasing alongside the severity of the disease. A prospective trial echoed this finding, showing that patients on continuous maintenance reported better symptom scores and higher satisfaction, particularly in the early months of maintenance.¹⁶

Lifestyle Changes and Their Effect on Healing

Medication does the heavy lifting for esophagitis healing, but lifestyle changes can make a real difference in both the initial healing phase and in preventing relapse. Weight loss has the strongest evidence behind it. A large population study found a dose-dependent relationship between weight loss and symptom reduction, with the odds of losing reflux symptoms increasing roughly fourfold in people on medication who reduced their BMI by more than 3.5 units compared to those who lost less than half a unit.¹⁷ Elevating the head of your bed and avoiding meals within two to three hours of lying down are widely recommended, particularly given the role of nighttime acid exposure in healing failure.

These measures aren’t a substitute for acid suppression when you have visible erosive disease, but they can be the difference between a PPI working well enough and falling just short. For people trying to step down to on-demand therapy after healing, weight management is one of the most effective ways to keep relapse at bay.

When Esophagitis Doesn’t Look Like GERD

Not all esophageal inflammation that responds to PPIs is caused by acid reflux. Eosinophilic esophagitis (EoE) is an immune-mediated condition that can look similar to GERD-related esophagitis and can even respond to PPI therapy. Research into this overlap found that the inflammatory and genetic markers in PPI-responsive esophageal eosinophilia were essentially indistinguishable from those in classic EoE, with PPI treatment downregulating the same allergic and inflammatory pathways in both conditions.¹⁸ If your esophagitis keeps recurring despite good acid control, or if your primary symptom is food getting stuck rather than heartburn, eosinophilic esophagitis is worth investigating. Treatment and long-term management differ from standard GERD care.

What Happens When Esophagitis Goes Untreated

Chronic, unhealed esophagitis isn’t just uncomfortable. Ongoing acid damage can lead to scarring that narrows the esophagus, a condition called a peptic stricture. These strictures tend to occur in the context of inadequately treated reflux and are more common in elderly patients.¹⁹ They cause progressive difficulty swallowing and often require dilation procedures in addition to aggressive acid suppression.

Long-standing esophagitis also raises the risk of Barrett’s esophagus, a condition in which the normal lining of the esophagus is replaced by a type of tissue that resembles the intestinal lining. This change, called intestinal metaplasia, is driven by chronic reflux damage and is considered a precursor to esophageal adenocarcinoma.²⁰ The length of the Barrett’s segment correlates with the length of esophageal inflammation.²¹ Risk factors for developing Barrett’s include male sex, older age, family history, long-standing GERD, smoking, and obesity measured by waist-to-hip ratio.²² These complications reinforce why treating esophagitis to full mucosal healing, rather than just symptom relief, matters for long-term health.

Healing in Older Adults

Age complicates esophagitis healing in several ways. Older adults tend to have more acid exposure than younger people with the same condition. Research has shown that in patients over 65, the percentage of the day spent with an esophageal pH below 4 was roughly two and a half times higher than in younger adults with reflux esophagitis.²³ This greater acid burden means older patients often present with more severe esophagitis at diagnosis and may need higher PPI doses or longer treatment to reach the same healing endpoint. Complicating matters, older adults are more likely to have a hiatal hernia, to take medications that relax the esophageal sphincter or irritate the lining, and to have reduced esophageal motility that impairs acid clearance. The combination of these factors means the “standard” eight-week timeline is often an underestimate in this group.

There is also a practical concern about long-term PPI use in older adults, given that prolonged acid suppression has been associated with modestly increased risks of bone fractures, kidney disease, and certain infections. These risks are generally small relative to the benefit of healing severe esophagitis, but they do push clinicians to reevaluate whether the lowest effective dose is being used once healing is confirmed. For older patients with mild disease that has healed, on-demand therapy or stepping down to an H2 blocker can be a reasonable strategy to reduce cumulative PPI exposure while still managing breakthrough symptoms.

Mucosal-protective agents, including alginate-based products and newer formulations combining hyaluronic acid with chondroitin sulfate, have been explored as adjuncts that might reduce the need for long-term high-dose acid suppression. These products aim to reinforce the esophageal lining against acid damage rather than simply reducing acid production. While they aren’t a replacement for PPIs in active erosive disease, combining mucosal protection with acid suppression may help in cases that respond only partially to PPIs alone.²⁴ For patients who want to reduce their PPI dose after healing, adding a mucosal protectant is one of the strategies being studied as a bridge.